Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations by removing those portions that reflect approval of eight new animal drug applications (NADAs). In a notice published elsewhere in this issue of the Federal Register, FDA is withdrawing approval of these NADAs.
This rule is effective November 5, 2010.Start Further Info
FOR FURTHER INFORMATION CONTACT:
John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: email@example.com.End Further Info End Preamble Start Supplemental Information
Fort Dodge Animal Health, a Division of Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017 has requested that FDA withdraw approval of the eight NADAs listed in Table 1 of this document because they are no longer manufactured or marketed.
|NADA No.||Product||Established name of drug(s)|
|NADA 11-141||UNISTAT-2 Type A medicated article||nitromide and sulfanitran.|
|NADA 14-250||NOVASTAT Type A medicated article||aklomide and sulfanitran.|
|NADA 34-536||ALKOMIX Type A medicated article ALKOMIX-3 Type A medicated article||aklomide. aklomide, sulfanitran, and roxarsone.|
|NADA 34-537||NOVASTAT-3 Type A medicated article||aklomide, sulfanitran, and roxarsone.|
|NADA 35-388||NOVASTAT-W Soluble Powder||aklomide and sulfanitran.|
|NADA 39-666||UNISTAT-3 Type A medicated article||nitromide, sulfanitran, and roxarsone.|
|NADA 44-015||TRAMISOL Type A medicated article||levamisole.|
|NADA 45-455||TRAMISOL Type A medicated article||levamisole.|
In a notice published elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADA 11-141, 14-250, 34-536, 34-537, 35-388, 39-666, 44-015, and 45-455, and all supplements and amendments thereto, is withdrawn, effective November 5, 2010. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these withdrawals of approval.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects
List of SubjectsEnd List of Subjects Start Amendment Part
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part
2. Remove § 520.2320.End Amendment Part Start Part
PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOODEnd Part Start Amendment Part
3. The authority citation forEnd Amendment Part
4. Remove § 556.30.End Amendment Part
5. Remove § 556.220.End Amendment Part
6. Remove § 556.680.End Amendment Part Start Part
PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDSEnd Part Start Amendment Part
7. The authority citation forEnd Amendment Part
8. In § 558.4, in paragraph (d), in the “Category I” table, remove the listing for “Aklomide”; and in the “Category II” table, remove the listings for “Levamisole”, “Nitromide” immediately followed in sequence by “Sulfanitran”, “Nitromide” immediately followed in sequence by “Sulfanitran” and by “Roxarsone”; “Sulfanitran” immediately followed in sequence by “Aklomide”, and the two listings for “Sulfanitran” immediately followed in sequence by “Aklomide” and by “Roxarsone”.End Amendment Part
9. Remove § 558.35.End Amendment Part
10. Remove § 558.315.End Amendment Part
11. Remove § 558.376.End Amendment Part Start Signature
Dated: October 8, 2010.
Director, Center for Veterinary Medicine.
[FR Doc. 2010-27011 Filed 10-25-10; 8:45 am]
BILLING CODE 4160-01-P